Clinical trial
Safety and Effectiveness of the Oral HIV Entry Inhibitor Vicriviroc in HIV…
NCT00082498 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00082498 |
|---|---|
| Title | Safety and Effectiveness of the Oral HIV Entry Inhibitor Vicriviroc in HIV Infected Patients |
| Official title | Phase II, Randomized, Double-Blind Study of the Safety and Efficacy of Vicriviroc (An Orally Administered HIV-1 Entry Inhibitor) in HIV-Infected, Treatment-Experienced Subjects |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Collaborators | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | SCH-D (vicriviroc), Placebo |
| Enrollment | 119 |
| Start date | May 1, 2004 |
| Primary completion | Dec 1, 2005 |
| Completion | Jan 1, 2011 |
| First posted | May 12, 2004 |
| Last update posted | Nov 1, 2021 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: